The Claim
Omega-3 fatty acid supplementation has no significant effect on alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, or low-density lipoprotein (LDL) levels in adults with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking omega-3 fatty acid supplements does not change levels of ALT, AST, total cholesterol, or LDL in adults with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.
See the scientific wording
Omega-3 fatty acid supplementation does not significantly alter alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, or low-density lipoprotein (LDL) levels in adults with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis, indicating limited impact on general liver injury or overall cholesterol metabolism.
Omega-3 fatty acids enter liver cells and turn on genes that break down fats for energy while turning off genes that make new fats. This reduces fat buildup in the liver, but it does not change the release of liver injury markers or the amount of cholesterol and LDL in the blood because these processes are controlled by different pathways.
What the research says
1 studyStudy: Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis
This study found that taking omega-3 supplements doesn’t reliably lower ALT, AST, total cholesterol, or LDL in people with fatty liver disease — meaning they don’t consistently fix these specific signs of liver stress or high cholesterol.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.